Nonproteolytic roles of 19S ATPases in transcription of CIITApIV genes.

PLoS One

Graduate Program in Cell Biology and Immunology, Department of Biology, Georgia State University, Atlanta, Georgia, United States of America.

Published: January 2016

Accumulating evidence shows the 26S proteasome is involved in the regulation of gene expression. We and others have demonstrated that proteasome components bind to sites of gene transcription, regulate covalent modifications to histones, and are involved in the assembly of activator complexes in mammalian cells. The mechanisms by which the proteasome influences transcription remain unclear, although prior observations suggest both proteolytic and non-proteolytic activities. Here, we define novel, non-proteolytic, roles for each of the three 19S heterodimers, represented by the 19S ATPases Sug1, S7, and S6a, in mammalian gene expression using the inflammatory gene CIITApIV. These 19S ATPases are recruited to induced CIITApIV promoters and also associate with CIITA coding regions. Additionally, these ATPases interact with elongation factor PTEFb complex members CDK9 and Hexim-1 and with Ser5 phosphorylated RNA Pol II. Both the generation of transcripts from CIITApIV and efficient recruitment of RNA Pol II to CIITApIV are negatively impacted by siRNA mediated knockdown of these 19S ATPases. Together, these results define novel roles for 19S ATPases in mammalian gene expression and indicate roles for these ATPases in promoting transcription processes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953376PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091200PLOS

Publication Analysis

Top Keywords

19s atpases
20
gene expression
12
roles 19s
8
define novel
8
mammalian gene
8
rna pol
8
atpases
7
19s
6
ciitapiv
5
gene
5

Similar Publications

Article Synopsis
  • The article discusses the challenges of treating intrahepatic cholangiocarcinoma (iCCA), as most patients do not respond well to existing therapies and highlights ongoing efforts to find new molecular targets.
  • It focuses on a study by Tang which examines the role of the PSMD6 gene in iCCA cells, finding it crucial for cell proliferation and overexpressed in iCCA tissues, although the study has limitations regarding its methods and insights into mechanisms.
  • The editorial also mentions recent advancements in targeted drug therapies and immunotherapies for iCCA, and underscores the potential of CRISPR technology and other computational methods in cancer research.
View Article and Find Full Text PDF

PSMC5 insufficiency and P320R mutation impair proteasome function.

Hum Mol Genet

August 2024

Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, United Kingdom.

The ubiquitin-proteasome system mediates the degradation of a wide variety of proteins. Proteasome dysfunction is associated with neurodegenerative diseases and neurodevelopmental disorders in humans. Here we identified mutations in PSMC5, an AAA ATPase subunit of the proteasome 19S regulatory particle, in individuals with neurodevelopmental disorders, which were initially considered as variants of unknown significance.

View Article and Find Full Text PDF

Depletion of proteasome subunit PSMD1 induces cancer cell death via protein ubiquitination and DNA damage, irrespective of p53 status.

Sci Rep

April 2024

Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Korea University, 75, Nowon-Ro, Nowon-Gu, Seoul, 01812, South Korea.

Hepatocellular carcinoma (HCC) is characterized by high incidence and fatality rates worldwide. In our exploration of prognostic factors in HCC, the 26s proteasome subunit, non-ATPase 1 (PSMD1) protein emerged as a significant contributor, demonstrating its potential as a therapeutic target in this aggressive cancer. PSMD1 is a subunit of the 19S regulatory particle in the 26S proteasome complex; the 19S particle controls the deubiquitination of ubiquitinated proteins, which are then degraded by the proteolytic activity of the complex.

View Article and Find Full Text PDF

Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers.

Bioorg Med Chem Lett

October 2023

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States. Electronic address:

The ubiquitin-proteasome system serves as the major proteolytic degradation pathway in eukaryotic cells. Many inhibitors that covalently bind to the proteasome's active sites have been developed for hematological cancers, but resistance can arise in patients. To overcome limitations of active-site proteasome inhibitors, we and others have focused on developing ligands that target subunits on the 19S regulatory particle (19S RP).

View Article and Find Full Text PDF

Molecular mechanism for activation of the 26S proteasome by ZFAND5.

Mol Cell

August 2023

Department of Systems Biology, Harvard Medical School, Boston, MA USA. Electronic address:

Various hormones, kinases, and stressors (fasting, heat shock) stimulate 26S proteasome activity. To understand how its capacity to degrade ubiquitylated proteins can increase, we studied mouse ZFAND5, which promotes protein degradation during muscle atrophy. Cryo-electron microscopy showed that ZFAND5 induces large conformational changes in the 19S regulatory particle.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!